PDS Biotechnology Corp (PDSB : NASDAQ)
Common Stock
$0.99
USD
+0.41 (69.25%)
Last updated: 2026-09-16
Get PDSB alerts:
PDSB
PDS Biotechnology Corp
WealthAwesomePerformance
1 Day
+69.25%
1 Week
+238.09%
1 Month
+348.24%
YTD
+8.98%
Key Statistics
Market Cap
$71.79M
52W High
$1.55
52W Low
$0.20
P/E Ratio
-
50 Day MA
$0.49
200 Day MA
$0.80
Beta
1.45
Dividend Yield
-
Advertisement
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 9/16/2026 | $0.65 | $1.06 | $0.62 | $0.99 | $0.99 | 193,676,886 |
| 9/15/2026 | $0.49 | $0.76 | $0.41 | $0.59 | $0.59 | 372,179,892 |
| 9/14/2026 | $0.28 | $0.45 | $0.26 | $0.40 | $0.40 | 80,847,334 |
| 9/11/2026 | $0.32 | $0.32 | $0.29 | $0.29 | $0.29 | 5,839,190 |
| 9/10/2026 | $0.29 | $0.33 | $0.28 | $0.32 | $0.32 | 12,732,500 |
| 9/9/2026 | $0.30 | $0.32 | $0.28 | $0.29 | $0.29 | 19,253,100 |
| 9/8/2026 | $0.49 | $0.65 | $0.26 | $0.30 | $0.30 | 491,124,600 |
| 9/4/2026 | $0.22 | $0.24 | $0.22 | $0.22 | $0.22 | 1,083,600 |
| 9/3/2026 | $0.21 | $0.23 | $0.21 | $0.22 | $0.22 | 832,600 |
| 9/2/2026 | $0.20 | $0.22 | $0.20 | $0.21 | $0.21 | 765,000 |
Analyst Price Targets
Based on 3 analysts covering PDSB · as of Sep 17, 2026
Wall Street analysts forecast PDSB stock price to rise 379.5% over the next 12 months.
Consensus
Strong Buy4.67 / 5.00
Avg. Target
US$4.75
+379.5% Upside
Current Price
US$0.99
Last close
Analyst Breakdown (3 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on PDSB's historical volatility
30-Day Vol
388.8%
Annualized
90-Day Vol
270.5%
Annualized
Trend (90d)
+21.6%
Annualized drift
90d Mean
US$1.07
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | US$1.02 | US$0.27 – US$3.89 |
| 60 trading days | US$1.04 | US$0.16 – US$6.95 |
| 90 trading days | US$1.07 | US$0.10 – US$10.93 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About PDS Biotechnology Corp
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101, a Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein for treating acute myeloid leukemia, prostate, and breast cancer; and PDS0103 for ovarian, breast, colorectal, and lung cancers. In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate, tumor-targeting interleukin 12 immune-cytokine that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment. It has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, Georgia Research Foundation, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is based in Princeton, New Jersey.
Financials
- Revenue (TTM)
- $0
- EBITDA
- $-27.77M
- Profit Margin
- 0.00%
- ROE (TTM)
- -543.97%
- EPS (Diluted)
- -1.08
- Book Value
- -0.06
Classification
- Sector
- Health Care
- Industry
- Biotechnology
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Advertisement
Common Questions About PDSB.US
Market movers
Recent NASDAQ movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| DLXY | Delixy Holdings Limited Ordinary Shares | $2.29 | +451.81% |
| MEDS | DataMEDS AI, Inc. | $6.07 | +274.69% |
| SNYR | Synergy CHC Corp. Common Stock | $0.27 | +234.15% |
| QCLS | Q/C Technologies, Inc. | $0.96 | +118.45% |
| AEHL | Antelope Enterprise Holdings Ltd | $9.22 | +78.68% |
| ZTG | Zenta Group Company Limited | $1.18 | +75.33% |
| TPST | Tempest Therapeutics Inc | $1.21 | +60.18% |
| AMPGZ | Amplitech Group, Inc. Series B Right | $0.19 | +41.54% |